Colchicine as an Adjunctive Therapy to Improve Ischemic Stroke Reperfusion Outcomes in Mice
Colchicin als Zusatztherapie zur Verbesserung der Reperfusionsoutcomes beim ischämischen Schlaganfall bei Mäusen
CNS Neuroscience & Therapeutics · 2026-07 · 32 (7)
DOI: 10.1002/cns.70922 ↗Auf einen Blick
Im Mausmodell eines ischämisch-reperfusionellen Schlaganfalls verbesserte Colchicin bei Reperfusion die Mikrozirkulation und verringerte Hirnschädigung. Die Effekte hingen von Neutrophilen ab.
Fragestellung
Verbessert Colchicin als Zusatztherapie bei Reperfusion die Outcomes nach ischämischem Schlaganfall im Mausmodell?
Methode
tMCAO-Mausmodell; Colchicin 0,8 mg/kg intraperitoneal bei Reperfusion; Beurteilung von Neutrophilen, NETs, BBB, Hirndurchblutung, Entzündung und Langzeitfolgen bis 14 Tage.
Ergebnisse
Colchicin senkte Neutrophilenanstieg und -aktivierung, NETs und Mikrogefäß-Fibrin(ogen)-Ablagerungen. Hirndurchblutung und BBB-Integrität besserten sich, Infarktgröße und chronischer Gewebeverlust nahmen ab.
Schlussfolgerung der Autor:innen
Colchicin bei Reperfusion unterdrückt neutrophilengetriebene Thrombo-Inflammation, erhält die BBB-Integrität und verbessert die Hirndurchblutung; dadurch werden Hirnschädigung und neurologische Defizite reduziert.
Kernaussagen
- Colchicin wurde bei Reperfusion im Mausmodell gegeben
- Weniger NETs, Mikrogefäß-Ablagerungen und BBB-Schädigung
- Langzeit-Neurologie und Gewebeverlust waren verbessert
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 09.07.2026. Verfasst von Danni Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Colchicine, Ischemic Stroke, Reperfusion Injury. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Heart Association.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Mechanical thrombectomy (MT) has become a cornerstone therapy for acute ischemic stroke (AIS) caused by large‐vessel occlusion; however, incomplete microvascular reperfusion and blood–brain barrier (BBB) disruption frequently limit its clinical benefit. Emerging evidence implicates neutrophil‐driven thrombo‐inflammation, particularly neutrophil extracellular trap (NET)–mediated microvascular obstruction, as a key mechanism underlying post‐reperfusion hypoperfusion and secondary neurovascular injury. Colchicine, an FDA‐approved microtubule inhibitor, potently suppresses neutrophil effector functions with a favorable safety profile, making it a promising adjunct to ischemia–reperfusion.
Methods
Using a transient middle cerebral artery occlusion (tMCAO) mouse model of ischemia–reperfusion, colchicine (0.8 mg/kg, intraperitoneal) was administered at reperfusion. We assessed circulating neutrophil response and activation, neutrophil F‐actin polymerization, NET formation, microvascular fibrin(ogen) deposition, cerebral blood flow, leukocyte brain infiltration, BBB integrity, and neuroinflammation at acute and subacute time points. Whole‐blood phagocytosis and bone marrow cellularity were examined at Day 3 after tMCAO. Neutrophil depletion was achieved using an anti‐Ly6G antibody. Long‐term neurological outcomes and brain tissue loss were evaluated up to 14 days after tMCAO.
Results
Colchicine administration at reperfusion significantly blunted early neutrophil increase and activation, inhibited neutrophil F‐actin polymerization, and suppressed intravascular NET formation and microvascular fibrin(ogen) deposition in tMCAO mice. It also improved cerebral blood flow, reduced leukocyte brain infiltration, attenuated BBB disruption, and decreased infarct size. Importantly, colchicine‐treated mice exhibited sustained improvements in sensorimotor and cognitive function and reduced chronic brain tissue loss. Notably, colchicine did not exacerbate post‐stroke immunosuppression, and its neuroprotective effects were abolished by neutrophil depletion.
Conclusions
Colchicine administered at reperfusion suppresses neutrophil‐driven thrombo‐inflammation, preserves BBB integrity, and improves cerebral blood flow, resulting in reduced ischemic brain injury and long‐term neurological deficits after ischemic stroke. These findings suggest colchicine might be developed as a potential adjunctive therapy to limit reperfusion‐associated microvascular dysfunction and neurovascular injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Neurosurgery and Neurology, Clinical Neuroscience Research Center, Tulane University School of Medicine, New Orleans, Louisiana, USA.
ORCID-Profile: Danni Wang, Yuwen Xiu, Ning Liu, Qiang Liu, Xiaoying Wang
Förderung
- American Heart Association
Zitieren
APA
Wang, D., Xiu, Y., Shi, M., Wang, Y., Zhou, D., Kilgore, M. D., Dumont, L., Sein, T. Y., Jiang, Y., Kazour, N., Liu, N., Dumont, A. S., Liu, Q., & Wang, X. (2026). Colchicine as an Adjunctive Therapy to Improve Ischemic Stroke Reperfusion Outcomes in Mice. CNS Neuroscience & Therapeutics, 32(7). https://doi.org/10.1002/cns.70922
Vancouver
Wang D, Xiu Y, Shi M, Wang Y, Zhou D, Kilgore MD, et al. Colchicine as an Adjunctive Therapy to Improve Ischemic Stroke Reperfusion Outcomes in Mice. CNS Neuroscience & Therapeutics. 2026;32(7). doi:10.1002/cns.70922
BibTeX
@article{Wang2026,
author = {Wang, Danni and Xiu, Yuwen and Shi, Mengxuan and Wang, Yingjie and Zhou, Di and Kilgore, Mitchell D and Dumont, Lauren and Sein, Thin Yadanar and Jiang, Yinghua and Kazour, Nicole and Liu, Ning and Dumont, Aaron S and Liu, Qiang and Wang, Xiaoying},
title = {Colchicine as an Adjunctive Therapy to Improve Ischemic Stroke Reperfusion Outcomes in Mice},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {7},
doi = {10.1002/cns.70922}
}
EUVIMED